Format

Send to

Choose Destination
Farm Hosp. 2015 Nov 1;39(6):350-4. doi: 10.7399/fh.2015.39.6.9037.

Efficacy and safety of alendronic acid in the treatment of osteoporosis in children.

Author information

1
Pharmacy Unit, Hospital General Universitario de Ciudad Real (Ciudad Real), Spain.. amsiguero@sescam.jccm.es.
2
Pharmacy Unit, Hospital General Universitario de Ciudad Real (Ciudad Real), Spain.. areas.vera@gmail.com.
3
Pharmacy Unit, Hospital General Universitario de Ciudad Real (Ciudad Real), Spain.. mtfranco@sescam.jccm.es.
4
Pharmacy Unit, Hospital General Universitario de Ciudad Real (Ciudad Real), Spain.. anaisafer86@hotmail.com.
5
Pharmacy Unit, Hospital General Universitario de Ciudad Real (Ciudad Real), Spain.. rpserrano@sescam.jccm.es.
6
Pharmacy Unit, Hospital General Universitario de Ciudad Real (Ciudad Real), Spain.. cencinas@sescam.org.

Abstract

in English, Spanish

OBJECTIVES:

to describe the efficacy and safety of the off-label use of alendronate in the treatment of osteoporosis in children and adolescents.

METHOD:

a retrospective study (2008-2014) of all patients under 18 years who were dispensed alendronate for this indication. The criteria for initiating treatment were: bone mineral density with a Z-score ≤ -2.5 SD, a past history of bone fractures without a previous traumatism, and persistent pain. The variables collected were: demographic, treatment-related, clinical. and safety data. The treatment was considered to be effective when there was an increase in bone mineral density up to a Z-score > -2.5 SD.

RESULTS:

a total of 12 patients, 8 of them male, with a mean age of 11 years (± 3 SD), were treated with alendronate. After a mean time of treatment of 2.15 years (± 1.2 SD), there was an increase in bone mineral density in all patients, 9 of which achieved a Z-score > -2.5 SD, so the drug was considered effective in 75% of cases. No patient had bone fractures or expressed adverse effects during treatment.

CONCLUSIONS:

alendronate increased bone mineral density and was well tolerated in all patients, therefore it could be considered as a therapeutic option in the treatment of osteoporosis in children.

PMID:
26618379
DOI:
10.7399/fh.2015.39.6.9037
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Aula Medica
Loading ...
Support Center